Clinical trials: Metastatic Colorectal Carcinoma
Colorectal Cancer Liver Metastasis
Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether RFA is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in overall survival compared with chemotherapy (target…
- Trial name
- NCT03127072
- Testing
- Radiofrequency Ablation (RFA), chemotherapy ± target therapy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Fudan University
Colorectal Cancer
Mechanistic and Molecular Study of the Process of Metastatic Dissemination in Colorectal Cancer
To confirm the role of the collective dissemination in the mechanisms of tumoral invasion of colorectal cancers
- Trial name
- DISCOVER (NCT03613194)
- Testing
- Sampling
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Colorectal Cancer
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
- Trial name
- CANTOR (NCT06792695)
- Testing
- Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
- Where
- 56 sites in United States, Australia and 10 more
- Volunteers
- 82 people
- Sponsor
- AstraZeneca
Cancer, Cancer Metastatic
Colorectal Liver Metastases: Novel Assessment Tools for Technical Resectability
The CoNoR study aims to assess whether the use of the LiMAx test and the HepaT1ca pre-operative planning magnetic resonance scan impact upon technical resectability decision-making in colorectal liver metastases (CLM).
- Conditions
- Cancer, Cancer Metastatic, Colorectal Cancer, Liver Metastasis Colon Cancer
- Trial name
- CoNoR (NCT04270851)
- Testing
- LiMAx test, HepaT1ca magnetic resonance scan
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Manchester
Colorectal Cancer
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer
- Trial name
- TARGET-D 203 (NCT07659795)
- Testing
- VS-7375, cetuximab, panitumumab
- Where
- 30 sites in United States, Australia
- Volunteers
- 150 people
- Sponsor
- Verastem, Inc.
Metastatic Colorectal Cancer
Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer
To estimate the progression free survival for subjects treated with panitumumab in combination with a chemotherapy regimen of oxaliplatin, 5-Fluorouracil (5-FU) and leucovorin (FOLFOX) as first-line chemotherapy regimen for…
- Trial name
- PULSE (NCT01288339)
- Testing
- Panitumumab + FOLFOX (DP), Panitumumab + FOLFOX (no-DP)
- Where
- 30 sites in Spain
- Volunteers
- 78 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Colorectal Cancer, Metastatic Colon Cancer
Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial
This research study is a randomized controlled trial that will observe changes in microbiome activity, changes in chemotherapy toxicity, and any changes in treatment outcomes between two groups of participants undergoing…
- Conditions
- Colorectal Cancer, Metastatic Colon Cancer, Metastatic Colorectal Cancer
- Trial name
- NCT06202183
- Testing
- Exercise Program
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Carcinoma in the Liver, Resectable Mass
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
This phase I trial studies the side effects and how well tremelimumab and durvalumab work in treating patients with colorectal cancer that has spread to the liver and can be removed by surgery.
- Conditions
- Metastatic Carcinoma in the Liver, Resectable Mass, Stage IV Colorectal Cancer AJCC v7, Stage IVA Colorectal Cancer AJCC v7
- Trial name
- NCT02754856
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Neoplasm Metastasis
Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer
This trial is designed to investigate the safety, tolerability and the effectiveness when OSI-774 (tarceva) is combined with oxaliplatin and capecitabine in treating patients with metastatic colorectal cancer.
- Trial name
- NCT00123851
- Testing
- Tarceva (OSI-774), Capecitabine, Oxaliplatin
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer, Metastatic to the Liver
Utility of Intra-operative Image Guidance System for Missing Metastases
Intraoperatively, the surgeon will interrogate the liver with ultrasound. The time spent by the surgeon using the ultrasound is recorded.
- Trial name
- NCT02806037
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colorectal Cancer
Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.
- Trial name
- CaboMAb (NCT02008383)
- Testing
- Panitumumab, Cabozantinib
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- John Strickler, M.D.
Colorectal Cancer
A Phase II Study on Dose Optimization of Fruquintinib in Elderly mCRC Patients Refractory to Standard Treatment（DOFEMCRC）
A Phase II study on dose optimization of fruquintinib in elderly metastatic colorectal cancer patients refractory to standard treatment.
- Trial name
- DOFEMCRC (NCT05025631)
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Zhen-Yu Ding
Colorectal Cancer, Liver Metastases
ctDNA-guided Adjuvant Chemotherapy in Liver Metastasis of Colorectal Cancer
The goal of this clinical trial is to compare in resectable colorectal cancer liver metastasis patients.The main question it aims to answer is whether the 3-year progression-free survival rate (PFS) of "watching and waiting" is…
- Conditions
- Colorectal Cancer, Liver Metastases, Circulating Tumor Cell, Chemotherapy Effect
- Trial name
- NCT05815082
- Testing
- Colorectal cancer resection combined with liver metastasis resection., FOLFOX chemotherapy regimen
- Where
- China
- Volunteers
- 490 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
A study of Avastin (bevacizumab) in combination chemotherapy in patients with metastatic cancer of the colon or rectum. The anticipated time on study treatment is until disease progression.
- Trial name
- NCT01131078
- Testing
- Bevacizumab [Avastin], Capecitabine, Irinotecan
- Where
- 44 sites in Italy
- Volunteers
- 306 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas
The purpose of this study is to confirm that linear quantification of CD3+ cells is a prognostic biomarker in localized colorectal carcinomas.
- Trial name
- CD3-OncoQuant (NCT02364024)
- Volunteers
- 856 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer
T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study
T regulatory lymphocytes were shown to be partly responsible for immune tolerance to cancer cells. In that respect these cells oppose to the mounting of an efficacious immune response needed to cure cancer.
- Trial name
- STARTREK (NCT00986518)
- Testing
- Adaptive autologous cell immunotherapy
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced or Metastatic Colorectal Cancer (mCRC)
Individual Patient Expanded Access to CA102N
This study is an individual patient expanded access protocol that the subject enrolled had completed the combination treatment of CA102N plus Lonsurf for at least 12 cycles.
- Trial name
- NCT05274204
- Testing
- CA102N
- Sponsor
- Holy Stone Healthcare Co., Ltd
Pancreatic Neoplasms, Hepatocellular Cancer
Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm
The purpose of the study is to evaluate whether the novel anti-cancer drug OXY111A is safe and tolerated in patients with primary and secondary hepato-pancreato-biliary and gastrointestinal neoplasia as measured by exploring the…
- Conditions
- Pancreatic Neoplasms, Hepatocellular Cancer, Cholangiocarcinoma, Colorectal Neoplasms
- Trial name
- OXY1A (NCT02528526)
- Testing
- OXY111A
- Where
- Switzerland
- Volunteers
- 69 people
- Sponsor
- University of Zurich
Metastatic Colorectal Cancer
Fruquintinib Sequential BEV+FOLFIRI vs. BEV+FOLFIRI Sequential Fruquintinib in Metastatic Colorectal Cancer
This is a prospective, open, multicenter, randomized controlled phase II study designed to observe the difference of efficacy, adverse events and quality of life between second-line and third-line application of Fruquintinib in…
- Trial name
- NCT05447715
- Testing
- Fruquintinib
- Where
- China
- Volunteers
- 134 people
- Sponsor
- Weijian Guo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.